Keywords: specific immunotherapy, allergy, anti-allergy vaccine

Abstract: Specific immunotherapy is the administration of graded amounts of an allergen vaccine in an allergic individual in order to achieve a dose that ameliorates the symptoms associated with exposure to sensitizing allergen. Anti-allergy vaccine is used to treat allergies, by modifying the immune response. Anti-allergy vaccine is indicated in many allergic diseases. Specific immunotherapy can reduce the use of symptomatic treatments, the number of consultations for disease flare-ups.

Can you cure allergies?

CORINA PORR

County Clinical Emergency Hospital Sibiu

Keywords: anti-allergic, vaccine

Abstract: Immunoterapia specifică este administrarea gradată a unor cantități dintr-un vaccin alergic la un individ alergic, pentru a atinge o doză care ameliorează simptomele asociate expunerii la alergenul sensibilizant. Vaccinul antialergic este utilizat în tratamentul alergiilor, prin modificarea răspunsului imun. Vaccinul antialergic este indicat în multe afecțiuni alergice. Prin immunoterapia specifică, se reduce mult utilizarea tratamentelor simptomatice, scăd numărul de vizite pentru puseele de exacerbare a boli.

This is the questions that one in four persons has in mind, given that the incidence of allergic diseases has increased in the last years. Allergen vaccine immunotherapy is the only curative treatment of allergy and asthma.

What is immunotherapy with allergen vaccine? The European Society of Allergy and Clinical Immunology (EAACI) defined allergen-specific immunotherapy (SIT) to be the gradual administration of vaccine amounts of allergen in an allergic individual to achieve a dose that improves the symptoms associated with exposure to sensitizing allergen. Anti-allergy vaccine is an allergen solution obtained by a special method of preparation of the allergens, which allows the extraction of the active constituents of animal or plant which may then be used in the treatment of allergy, by modifying the immune response.(1)

Who can receive an anti-allergy vaccine?

- Anti-allergy vaccine is indicated in:
  1. Hymenoptera venom allergy;
  2. Allergic rhinitis (moderate, severe);(2)
  3. Allergic conjunctivitis (moderate, severe);
  4. Asthma (mild, moderate, persistent);
  5. Allergy to pollen (birch, Ambrose etc.);
  6. Allergy to house dust mites;
  7. Allergy to cats;
  8. Food allergy;
  9. Allergy to drugs.

In Hymenoptera venom allergy, allergen-specific immunotherapy is indicated in the following cases:

- The existence of moderate or severe allergy reaction;
- Re-exposure likelihood (beekepers and their relatives);
- Minimum age 5 years (no maximum);
- Diagnostic tests positive: skin tests or specific IgE (RAST, CAP-system).

SIT is not performed in patients with severe reaction, but negative specific IgE (in this case, anaphylactoid reaction). It is only done by subcutaneous injection. The method of SIT until reaching the maintenance dose is classical (lasting months), rush (which takes days) ultra rush (24-48h) and only with the patient's hospitalization. ITS duration for Hymenoptera is over eight years, and the success rate is of 95%

SIT major indication in allergic rhinitis is for moderate/severe allergic rhinitis. Symptoms MUST be present more than two consecutive seasons (3,4,5,6,7,8) with pollen (birch, Ambrose, olive etc.); the success rate is of 90-95%. In house dust mites allergy, the success rate of SIT is of 60-70%. In moderate / severe allergic conjunctivitis, the results are less spectacular as compared with allergic rhinitis.

Food allergy has no major indication, except cases of severe anaphylactic events (milk, peanuts).(11-15) It is preferred that the vaccine containing the allergen be altered by enzymatic action, in which case, it is called the enzyme-potentiated desensitization).

The allergic medication is recommended to be replaced by another class of drugs. SIT is carried out only if specific IgE-mediated reaction and tolerance is achieved in hours or days. Dose administration is increased every 20-30 min during hospitalization and only with the written consent of the patient. There is a risk of anaphylactic reactions (30-80% penicillin).(16) Other drugs undergoing SIT: biseptol, antibiotics, chemotherapy, sulfasalazine, nonsteroid anti-inflammatory drugs.(17)

Atopic dermatitis is not a major indication of SIT. Favourable results have been obtained in a small number of children in the case of mites and those associated with asthma.

In the allergy to moulds (Alternaria, Cladosporium), SIT is indicated if they cannot be avoided and pharmacotherapy does not lead to satisfactory results, but studies are few.

The latex allergy is not treated by SIT, avoidance and replacement of latex products is recommended.

But SIT has absolute contraindications:

1. When there is not a condition subject to an allergen;

Corinda Sibiu

Corresponding author: Corinda Sibiu, Str. Reșița, Nr. 95/12, Sibiu, România, E-mail: corinda_sibiu@yahoo.com, Tel: +40723 083974

Article received on 20.02.2014 and accepted for publication on 28.04.2014

ACTA MEDICA TRANSILVANICA June 2014;2(2):202-204

CLINICAL ASPECTS

2. The existence of severe illness (cancer, cirrhosis, hepatitis, cardiovascular disease, kidney);
3. The presence of autoimmune diseases;
4. The presence of immunodeficiency;
5. Disease at high risk for serious reactions to the administration of epinephrine, using β-blockers, ACE;
6. Asthma unstable;
7. Patient refusal;
8. Repeated severe reactions.

Relative contraindications are:
1. Age <5 years for subcutaneous ITS and <2 years for sublingual;
2. Age > 50 years, especially if the patients have cardiovascular disease;
3. In the period before or during pregnancy and lactation;
4. Patients on β-blockers may be switched to a different class of antihypertensive drugs, then SIT may be initiated.

The success of the SIT lies in the selection of patients. They must meet certain conditions

1. Be allergic and with documented conditioning between the allergen exposure and symptoms;
2. Present allergen-specific IgE (skin tests or serum dosage);
3. The allergen cannot be avoided;
4. The disease is not lengthy prior to SIT or has not reached the stage of tissue remodelling;
5. It is initiated when the disease is controlled;
6. Patients who do not respond adequately to standard therapy;
7. Patients to be compliant;
8. Who administers the anti-allergy vaccine?

SIT can be applied only by the allergologist as only this one can decide in what patients can apply it and in case of adverse effects, the allergologist is the most indicated person to treat them.

Ways of managing SIT are:

Table no. 1. SIT administration ways

<table>
<thead>
<tr>
<th>SIT mode of administration</th>
<th>SIT characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subcutaneous (parenteral)</td>
<td>Named as classic. It was first used and is the most commonly used</td>
</tr>
<tr>
<td>Sublingual (swallow or spit)</td>
<td>Favourable results (pollen)</td>
</tr>
<tr>
<td>Oral</td>
<td>New</td>
</tr>
<tr>
<td>Nasal inhalation</td>
<td>Useful for adults. The effects on children not known</td>
</tr>
<tr>
<td>Bronchial inhalation</td>
<td>Under evaluation</td>
</tr>
<tr>
<td>Intranganglionary (3 months)</td>
<td>For Hymenoptera</td>
</tr>
</tbody>
</table>

EAACI proposed for treatment only subcutaneous and sublingual (oral) routes.

Modes of administration of SIT are

1. Slow: 3-5 months (each scheme adapts to each patient);(18)
2. Rush: 1-2 weeks (insects, drugs);

Figure no. 1. Local reaction at the injection site

Syndrome reactions consist of nasal and bronchial symptoms.
Systemic reactions can be anaphylactic shock, generalized urticaria, severe asthma attack, severe angioedema (larynx). These are rarer than the local reactions and occur within the first 30 minutes when administering the vaccine. Surveillance in the surgery is the first 30 minutes after vaccine administration.(19)

What are the benefits allergic vaccines?
This results in reducing allergy symptoms, reducing the need for medication, quality of life, improved functional status, cost reduction, it prevents progression from allergic rhinitis to asthma (20-24), prevents multi-sensitization.(25,26)
ITS mechanism is shown in the figure below:
Factors that negatively influence the effectiveness of SIT are lack of patient’s compliance, patient awareness amendment, and intolerance of an optimal dose, lack of accurate diagnosis

What are the costs?
SIT vaccine is expensive in price, it addresses specialized medical service, and it has long period of treatment. But an SIT is cheaper for a period of six months, compared with daily administration in the same period of a non-sedating antihistamine as a single dose.
Though SIT, symptomatic treatments may be reduced, as well as the number of visits for exacerbation of disease flares.

In conclusion, SIT may be a cheaper alternative in the therapeutic program of an allergic patient.

Figure no. 2. SIT mechanism


REFERENCES